Home
Mesoblast Ltd
83% Survival in COVID-19 ARDS Patients with Remestemcel-L
Business
Apr 24 2020
3 min read

83% Survival in COVID-19 ARDS Patients with Remestemcel-L

news images

Mesoblast Ltd has released a press release.

View Attachment